Target intelligence / Profile preview

T-complex protein 1 subunit zeta-2 (CCT6B)

Target
CCT6B
Molecular classification
Chaperonin, Protein folding complex (part of the chaperonin-containing TCP1 complex, also called TRiC), Other (not a receptor, ion channel, enzyme, or transporter; but a protein folding chaperone)
01

Overview

T-complex protein 1 subunit zeta-2 (CCT6B) is a molecular chaperone and a component of the chaperonin-containing TCP1 complex (also called TRiC). This complex consists of two rings, each with eight unique subunits, which function collaboratively to fold newly synthesized polypeptides such as actin and tubulin in an ATP-dependent manner. CCT6B is expressed in various tissues, including testis, and plays a role in protein folding, cytoskeletal organization, and potentially tissue-specific processes. While most CCT subunits are overexpressed in several cancers and linked to poor prognosis, CCT6B paradoxically shows reduced expression in hepatocellular carcinoma, and higher levels predict better patient survival, highlighting a unique role among chaperonin subunits[1][2][3].

Other names
CCT6BChaperonin containing TCP1 subunit 6BTCP-1-zeta-2Cctz2TSA303CCT-zeta-2CCTZ-2TCP-1-zeta-likeTestis-specific Tcp20Testis-specific protein TSA303CCT-zeta-likeChaperonin-containing T-complex polypeptide 1 subunit 6BT-complex protein 1 subunit zeta-2
02

Mechanism of action

No specific drugs directly targeting CCT6B; mechanism would theoretically be modulation of protein folding or chaperone activity.

03

Biological functions

Protein folding (ATP-dependent)Unfolded protein bindingMaintenance of cytoskeletal proteins such as actin and tubulinRegulation of telomere localization and maintenance
04

Disease associations

Cancer (associated with hepatocellular carcinoma, hematologic cancers, and shown to be prognostic in HCC)Bardet-Biedl Syndrome 10
05

Safety considerations

No established safety concerns or therapeutic challenges specific to CCT6B identified in current literature.
06

Biomarkers

CCT6B mRNA/protein levels can serve as biomarkers for prognosis in hepatocellular carcinoma (higher expression correlates with improved survival)

Beyond the preview

Go deeper on T-complex protein 1 subunit zeta-2 (CCT6B).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on T-complex protein 1 subunit zeta-2 (CCT6B).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call